In one recently published meta-analysis, including a total of 13 randomized controlled trials that evaluated the effects of SGLT2 inhibitors on cardiac remodeling in patients with T2DM and/or HF, SGLT2 inhibitors improved left ventricular (LV) ejection fraction, LV mass, LV mass index, LV end-systolic volume, LV end-systolic volume index, and E-wave deceleration time significantly (32). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.